Leerink Partners Upgrades AstraZeneca (AZN) to Outperform
Get Alerts AZN Hot Sheet
Price: $67.75 -0.75%
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
17 Buy, 8 Hold, 3 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Leerink Partners upgraded AstraZeneca (NYSE: AZN) from Market Perform to Outperform with a price target of $34.
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $26.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
- AstraZeneca (AZN) announces Ultomiris approved in the US for NMOSD
- Raymond James Upgrades Public Storage (PSA) to Strong Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!